COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach

Perry, Malorie; Gravenor, Michael; Cottrell, Simon; Bedston, Stuart; Roberts, Richard; Williams, Christopher; Salmon, Jane; Lyons, Jane; Akbari, Ashley; Lyons, Ronan; Torabi, Fatemeh; Griffiths, Lucy

doi:10.1080/21645515.2022.2031774

Journal article 874 views 97 downloads

COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach

Malorie Perry

, Michael Gravenor

, Simon Cottrell

, Stuart Bedston, Richard Roberts, Christopher Williams

, Jane Salmon, Jane Lyons

, Ashley Akbari

, Ronan Lyons

, Fatemeh Torabi

, Lucy Griffiths

Human Vaccines & Immunotherapeutics, Volume: 18, 2022, Issue: 1, Pages: 1 - 10

Swansea University Authors: Michael Gravenor , Stuart Bedston, Ashley Akbari , Ronan Lyons , Fatemeh Torabi , Lucy Griffiths

PDF | Version of Record

© 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License
Download (1.02MB)

Check full text

DOI (Published version): 10.1080/21645515.2022.2031774

Abstract

Vaccination programs against COVID-19 vary globally with estimates of vaccine effectiveness (VE) affected by vaccine type, schedule, strain, outcome, and recipient characteristics. This study assessed VE of BNT162b2 and ChAdOx1 vaccines against PCR positive SARS-CoV-2 infection, hospital admission,...

Full description

Published in:	Human Vaccines & Immunotherapeutics
ISSN:	2164-5515 2164-554X
Published:	Informa UK Limited 2022
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa59498
Tags:	Add Tag No Tags, Be the first to tag this record!

first_indexed	2022-03-21T12:48:55Z
last_indexed	2023-01-11T14:40:49Z
id	cronfa59498
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2022-10-27T10:59:38.8869656</datestamp><bib-version>v2</bib-version><id>59498</id><entry>2022-03-04</entry><title>COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach</title><swanseaauthors><author><sid>70a544476ce62ba78502ce463c2500d6</sid><ORCID>0000-0003-0710-0947</ORCID><firstname>Michael</firstname><surname>Gravenor</surname><name>Michael Gravenor</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>c79d07eaba5c9515c0df82b372b76a41</sid><firstname>Stuart</firstname><surname>Bedston</surname><name>Stuart Bedston</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>aa1b025ec0243f708bb5eb0a93d6fb52</sid><ORCID>0000-0003-0814-0801</ORCID><firstname>Ashley</firstname><surname>Akbari</surname><name>Ashley Akbari</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>83efcf2a9dfcf8b55586999d3d152ac6</sid><ORCID>0000-0001-5225-000X</ORCID><firstname>Ronan</firstname><surname>Lyons</surname><name>Ronan Lyons</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f569591e1bfb0e405b8091f99fec45d3</sid><ORCID>0000-0002-5853-4625</ORCID><firstname>Fatemeh</firstname><surname>Torabi</surname><name>Fatemeh Torabi</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>e35ea6ea4b429e812ef204b048131d93</sid><ORCID>0000-0001-9230-624X</ORCID><firstname>Lucy</firstname><surname>Griffiths</surname><name>Lucy Griffiths</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-03-04</date><deptcode>HDAT</deptcode><abstract>Vaccination programs against COVID-19 vary globally with estimates of vaccine effectiveness (VE) affected by vaccine type, schedule, strain, outcome, and recipient characteristics. This study assessed VE of BNT162b2 and ChAdOx1 vaccines against PCR positive SARS-CoV-2 infection, hospital admission, and death among adults aged 50 years and older in Wales, UK during the period 7 December 2020 to 18 July 2021, when Alpha, followed by Delta, were the predominant variants. We used individual-level linked routinely collected data within the Secure Anonymized Information Linkage (SAIL) Databank. Data were available for 1,262,689 adults aged 50 years and over; coverage of one dose of any COVID-19 vaccine in this population was 92.6%, with coverage of two doses 90.4%. VE against PCR positive infection at 28-days or more post first dose of any COVID-19 vaccine was 16.0% (95%CI 9.6–22.0), and 42.0% (95%CI 36.5–47.1) seven or more days after a second dose. VE against hospital admission was higher at 72.9% (95%CI 63.6–79.8) 28 days or more post vaccination with one dose of any vaccine type, and 84.9% (95%CI 78.2–89.5) at 7 or more days post two doses. VE for one dose against death was estimated to be 80.9% (95%CI 72.1–86.9). VE against PCR positive infection and hospital admission was higher for BNT162b2 compared to ChAdOx1. In conclusion, vaccine uptake has been high among adults in Wales and VE estimates are encouraging, with two doses providing considerable protection against severe outcomes. Continued roll-out of the vaccination programme within Wales, and globally, is crucial in our fight against COVID-19.</abstract><type>Journal Article</type><journal>Human Vaccines & Immunotherapeutics</journal><volume>18, 2022</volume><journalNumber>1</journalNumber><paginationStart>1</paginationStart><paginationEnd>10</paginationEnd><publisher>Informa UK Limited</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2164-5515</issnPrint><issnElectronic>2164-554X</issnElectronic><keywords>COVID-19 vaccines; vaccination; immunization; effectiveness; SARS-CoV-2; adult; Wales</keywords><publishedDay>3</publishedDay><publishedMonth>3</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-03-03</publishedDate><doi>10.1080/21645515.2022.2031774</doi><url/><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>WT_/Wellcome Trust/United Kingdom, MR/V028367/1/MRC_/Medical Research Council/United Kingdom.</funders><projectreference/><lastEdited>2022-10-27T10:59:38.8869656</lastEdited><Created>2022-03-04T16:51:56.2829005</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Malorie</firstname><surname>Perry</surname><orcid>0000-0003-1397-5934</orcid><order>1</order></author><author><firstname>Michael</firstname><surname>Gravenor</surname><orcid>0000-0003-0710-0947</orcid><order>2</order></author><author><firstname>Simon</firstname><surname>Cottrell</surname><orcid>0000-0003-0645-2764</orcid><order>3</order></author><author><firstname>Stuart</firstname><surname>Bedston</surname><order>4</order></author><author><firstname>Richard</firstname><surname>Roberts</surname><order>5</order></author><author><firstname>Christopher</firstname><surname>Williams</surname><orcid>0000-0002-5092-4987</orcid><order>6</order></author><author><firstname>Jane</firstname><surname>Salmon</surname><order>7</order></author><author><firstname>Jane</firstname><surname>Lyons</surname><orcid>0000-0002-4407-770x</orcid><order>8</order></author><author><firstname>Ashley</firstname><surname>Akbari</surname><orcid>0000-0003-0814-0801</orcid><order>9</order></author><author><firstname>Ronan</firstname><surname>Lyons</surname><orcid>0000-0001-5225-000X</orcid><order>10</order></author><author><firstname>Fatemeh</firstname><surname>Torabi</surname><orcid>0000-0002-5853-4625</orcid><order>11</order></author><author><firstname>Lucy</firstname><surname>Griffiths</surname><orcid>0000-0001-9230-624X</orcid><order>12</order></author></authors><documents><document><filename>59498__22637__16860491c9cd44e1bc194c49b4b71aaa.pdf</filename><originalFilename>59498.pdf</originalFilename><uploaded>2022-03-21T12:48:15.8025744</uploaded><type>Output</type><contentLength>1068114</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling	2022-10-27T10:59:38.8869656 v2 59498 2022-03-04 COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach 70a544476ce62ba78502ce463c2500d6 0000-0003-0710-0947 Michael Gravenor Michael Gravenor true false c79d07eaba5c9515c0df82b372b76a41 Stuart Bedston Stuart Bedston true false aa1b025ec0243f708bb5eb0a93d6fb52 0000-0003-0814-0801 Ashley Akbari Ashley Akbari true false 83efcf2a9dfcf8b55586999d3d152ac6 0000-0001-5225-000X Ronan Lyons Ronan Lyons true false f569591e1bfb0e405b8091f99fec45d3 0000-0002-5853-4625 Fatemeh Torabi Fatemeh Torabi true false e35ea6ea4b429e812ef204b048131d93 0000-0001-9230-624X Lucy Griffiths Lucy Griffiths true false 2022-03-04 HDAT Vaccination programs against COVID-19 vary globally with estimates of vaccine effectiveness (VE) affected by vaccine type, schedule, strain, outcome, and recipient characteristics. This study assessed VE of BNT162b2 and ChAdOx1 vaccines against PCR positive SARS-CoV-2 infection, hospital admission, and death among adults aged 50 years and older in Wales, UK during the period 7 December 2020 to 18 July 2021, when Alpha, followed by Delta, were the predominant variants. We used individual-level linked routinely collected data within the Secure Anonymized Information Linkage (SAIL) Databank. Data were available for 1,262,689 adults aged 50 years and over; coverage of one dose of any COVID-19 vaccine in this population was 92.6%, with coverage of two doses 90.4%. VE against PCR positive infection at 28-days or more post first dose of any COVID-19 vaccine was 16.0% (95%CI 9.6–22.0), and 42.0% (95%CI 36.5–47.1) seven or more days after a second dose. VE against hospital admission was higher at 72.9% (95%CI 63.6–79.8) 28 days or more post vaccination with one dose of any vaccine type, and 84.9% (95%CI 78.2–89.5) at 7 or more days post two doses. VE for one dose against death was estimated to be 80.9% (95%CI 72.1–86.9). VE against PCR positive infection and hospital admission was higher for BNT162b2 compared to ChAdOx1. In conclusion, vaccine uptake has been high among adults in Wales and VE estimates are encouraging, with two doses providing considerable protection against severe outcomes. Continued roll-out of the vaccination programme within Wales, and globally, is crucial in our fight against COVID-19. Journal Article Human Vaccines & Immunotherapeutics 18, 2022 1 1 10 Informa UK Limited 2164-5515 2164-554X COVID-19 vaccines; vaccination; immunization; effectiveness; SARS-CoV-2; adult; Wales 3 3 2022 2022-03-03 10.1080/21645515.2022.2031774 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University WT_/Wellcome Trust/United Kingdom, MR/V028367/1/MRC_/Medical Research Council/United Kingdom. 2022-10-27T10:59:38.8869656 2022-03-04T16:51:56.2829005 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Malorie Perry 0000-0003-1397-5934 1 Michael Gravenor 0000-0003-0710-0947 2 Simon Cottrell 0000-0003-0645-2764 3 Stuart Bedston 4 Richard Roberts 5 Christopher Williams 0000-0002-5092-4987 6 Jane Salmon 7 Jane Lyons 0000-0002-4407-770x 8 Ashley Akbari 0000-0003-0814-0801 9 Ronan Lyons 0000-0001-5225-000X 10 Fatemeh Torabi 0000-0002-5853-4625 11 Lucy Griffiths 0000-0001-9230-624X 12 59498__22637__16860491c9cd44e1bc194c49b4b71aaa.pdf 59498.pdf 2022-03-21T12:48:15.8025744 Output 1068114 application/pdf Version of Record true © 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach
spellingShingle	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach Michael Gravenor Stuart Bedston Ashley Akbari Ronan Lyons Fatemeh Torabi Lucy Griffiths
title_short	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach
title_full	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach
title_fullStr	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach
title_full_unstemmed	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach
title_sort	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach
author_id_str_mv	70a544476ce62ba78502ce463c2500d6 c79d07eaba5c9515c0df82b372b76a41 aa1b025ec0243f708bb5eb0a93d6fb52 83efcf2a9dfcf8b55586999d3d152ac6 f569591e1bfb0e405b8091f99fec45d3 e35ea6ea4b429e812ef204b048131d93
author_id_fullname_str_mv	70a544476ce62ba78502ce463c2500d6_*_Michael Gravenor c79d07eaba5c9515c0df82b372b76a41__Stuart Bedston aa1b025ec0243f708bb5eb0a93d6fb52__Ashley Akbari 83efcf2a9dfcf8b55586999d3d152ac6__Ronan Lyons f569591e1bfb0e405b8091f99fec45d3__Fatemeh Torabi e35ea6ea4b429e812ef204b048131d93_*_Lucy Griffiths
author	Michael Gravenor Stuart Bedston Ashley Akbari Ronan Lyons Fatemeh Torabi Lucy Griffiths
author2	Malorie Perry Michael Gravenor Simon Cottrell Stuart Bedston Richard Roberts Christopher Williams Jane Salmon Jane Lyons Ashley Akbari Ronan Lyons Fatemeh Torabi Lucy Griffiths
format	Journal article
container_title	Human Vaccines & Immunotherapeutics
container_volume	18, 2022
container_issue	1
container_start_page	1
publishDate	2022
institution	Swansea University
issn	2164-5515 2164-554X
doi_str_mv	10.1080/21645515.2022.2031774
publisher	Informa UK Limited
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	1
active_str	0
description	Vaccination programs against COVID-19 vary globally with estimates of vaccine effectiveness (VE) affected by vaccine type, schedule, strain, outcome, and recipient characteristics. This study assessed VE of BNT162b2 and ChAdOx1 vaccines against PCR positive SARS-CoV-2 infection, hospital admission, and death among adults aged 50 years and older in Wales, UK during the period 7 December 2020 to 18 July 2021, when Alpha, followed by Delta, were the predominant variants. We used individual-level linked routinely collected data within the Secure Anonymized Information Linkage (SAIL) Databank. Data were available for 1,262,689 adults aged 50 years and over; coverage of one dose of any COVID-19 vaccine in this population was 92.6%, with coverage of two doses 90.4%. VE against PCR positive infection at 28-days or more post first dose of any COVID-19 vaccine was 16.0% (95%CI 9.6–22.0), and 42.0% (95%CI 36.5–47.1) seven or more days after a second dose. VE against hospital admission was higher at 72.9% (95%CI 63.6–79.8) 28 days or more post vaccination with one dose of any vaccine type, and 84.9% (95%CI 78.2–89.5) at 7 or more days post two doses. VE for one dose against death was estimated to be 80.9% (95%CI 72.1–86.9). VE against PCR positive infection and hospital admission was higher for BNT162b2 compared to ChAdOx1. In conclusion, vaccine uptake has been high among adults in Wales and VE estimates are encouraging, with two doses providing considerable protection against severe outcomes. Continued roll-out of the vaccination programme within Wales, and globally, is crucial in our fight against COVID-19.
published_date	2022-03-03T04:16:51Z
_version_	1763754127464071168
score	11.037166

COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach

Similar Items